Ideas
mRNA melanoma vaccine success validates Moderna.
Moderna's personalized mRNA cancer vaccine succeeded in a large late-stage melanoma trial, validating the company's future beyond COVID and opening a potentially large new revenue source if approved as expected next year.
Buy Treasury steepener on buyback signal.
The Treasury's buyback expansion is a strong signaling event that calms long-end rate pressure and revives risk appetite; the most popular trade is a Treasury curve steepener, with a massive squeeze as crowded long-end shorts unwind before Jackson Hole.
Hynix buyback stabilizes stock; HBM dominance.
SK Hynix's near-$30 billion buyback is a shareholder-return policy designed to stabilize the stock, unwind dilutive ADR issuance, cancel shares, and support valuation while the company holds roughly 60% share in high-bandwidth memory.
Ten-year yields fall to 4.25%.
The 10-year Treasury yield is unlikely to sustain a move to 5%; UBS expects yields to fall back to about 4.25% by year-end and 4% by mid-next year, supported by Treasury buybacks and strong earnings conditions.
Buy equity dips on strong earnings.
Equity earnings growth is strong and estimates are being revised higher rather than trimmed, so while bond-driven volatility may persist into Jackson Hole and NVIDIA earnings, UBS would buy equity dips tied to bond-market volatility because earnings momentum should continue into year-end and the first half of next year.
AI semiconductor buildout remains intact.
The AI semiconductor buildout story remains intact for the next two years because hyperscaler backlogs are around $2.4 trillion, demand is expected to continue outstrip supply, and funding is not a problem even with higher bond yields and more equity issuance.
Healthcare attractive AI-free diversifier.
Healthcare is an attractive portfolio diversifier that is not tied to the AI capex story in the near term; it has been the top-performing sector over the last three months, offers innovation in GLP-1s, obesity/diabetes, and cancer, and is resuming earnings growth with valuation not extended.
Honeywell Aerospace drop overdone, upgrade says.
Honeywell Aerospace was upgraded after a 27% drop since the spin-off because investors may be punishing the stock too much; the customers are there and the main challenge is getting enough product out the door.
Dollar Tree shoppers return; upgrade.
Dollar Tree was upgraded as shoppers return, and analysts like the company's pricing actions and improving customer traffic even with Target still a threat.
Zoom more than video; rated Buy.
Zoom received a new Buy rating from Bank of America because the company is more than video calls and is becoming a bigger part of how people communicate at work, with earnings due next week.
Merck offers best cancer vaccine exposure.
Merck is the best way to play the melanoma vaccine data because it avoids the short-covering and dilution dynamics in Moderna, and the combination is setting up for a clinically meaningful, possibly 35%, reduction in melanoma recurrence risk.
Long-term Treasury yields face upward pressure.
The Treasury buyback announcement is a signal of discomfort with high long-term yields, but the fundamental drivers remain: fiscal concerns, inflation uncertainty, Fed reaction uncertainty, and heavy corporate issuance tied to AI spending. Any short-covering relief is likely temporary, with long-term rates facing renewed upward pressure.
Estée Lauder sales rebound drives surge.
Estee Lauder ended three years of falling annual sales and raised its outlook, putting shares on pace for their best day in 15 years.
Turnaround working; traffic comps accelerating.
Target's turnaround is working. The company posted good Q2 results on top of a good Q1, with same-store sales up 3.8% driven almost entirely by traffic up 3.6%, and customers are coming back to the brand and stores.
Tariff refunds make Lowe's beatable.
Lowe's guidance looks beatable because future tariff refunds are not yet baked into numbers, so reported results should come in better than the cautious outlook even though the housing-linked DIY consumer remains pressured.
Walmart quarter solid with share gains.
Walmart should have a solid quarter with same-store sales around 3.8%, continue to take share from weaker middle-market retailers, and deliver a strong enough result to get the stock moving again even without a guidance increase.
This Bloomberg Markets video, published August 19, 2026,
features Madison Muller, Michael Ball, Ed Ludlow, Nadia Lovell, Norah Mulinda, Sam Fazeli, Kathy Bostjancic, Joe Feldman
discussing MRNA, US Treasury Curve Steepener, 000660.KS, IEF, SPY, SMH, XLV, Honeywell Aerospace, DLTR, ZM, MRK, US30Y, EL, TGT, LOW, WMT.
16 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Madison Muller,
Michael Ball,
Ed Ludlow,
Nadia Lovell,
Norah Mulinda,
Sam Fazeli,
Kathy Bostjancic,
Joe Feldman
· Tickers:
MRNA,
US Treasury Curve Steepener,
000660.KS,
IEF,
SPY,
SMH,
XLV,
Honeywell Aerospace,
DLTR,
ZM,
MRK,
US30Y,
EL,
TGT,
LOW,
WMT
